Rick Bienkowski
Stock Analyst at Cantor Fitzgerald
(0.28)
# 4,094
Out of 4,835 analysts
38
Total ratings
12.5%
Success rate
-32.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Rick Bienkowski
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Reiterates: Overweight | $55 | $27.78 | +97.98% | 3 | May 14, 2025 | |
| VERV Verve Therapeutics | Upgrades: Overweight | n/a | $4.63 | - | 4 | Apr 15, 2025 | |
| BEAM Beam Therapeutics | Reiterates: Overweight | n/a | $17.89 | - | 12 | Mar 12, 2025 | |
| ACLX Arcellx | Initiates: Overweight | n/a | $58.78 | - | 1 | Sep 3, 2024 | |
| NTLA Intellia Therapeutics | Reiterates: Overweight | $65 | $8.50 | +664.71% | 7 | Jun 24, 2024 | |
| CRBU Caribou Biosciences | Initiates: Neutral | n/a | $0.94 | - | 1 | Nov 8, 2023 | |
| EDIT Editas Medicine | Reiterates: Overweight | $14 | $1.51 | +827.15% | 6 | Sep 13, 2023 | |
| CRSP CRISPR Therapeutics AG | Maintains: Outperform | $112 → $107 | $38.77 | +175.99% | 4 | Aug 8, 2022 |
Legend Biotech
May 14, 2025
Reiterates: Overweight
Price Target: $55
Current: $27.78
Upside: +97.98%
Verve Therapeutics
Apr 15, 2025
Upgrades: Overweight
Price Target: n/a
Current: $4.63
Upside: -
Beam Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: n/a
Current: $17.89
Upside: -
Arcellx
Sep 3, 2024
Initiates: Overweight
Price Target: n/a
Current: $58.78
Upside: -
Intellia Therapeutics
Jun 24, 2024
Reiterates: Overweight
Price Target: $65
Current: $8.50
Upside: +664.71%
Caribou Biosciences
Nov 8, 2023
Initiates: Neutral
Price Target: n/a
Current: $0.94
Upside: -
Editas Medicine
Sep 13, 2023
Reiterates: Overweight
Price Target: $14
Current: $1.51
Upside: +827.15%
CRISPR Therapeutics AG
Aug 8, 2022
Maintains: Outperform
Price Target: $112 → $107
Current: $38.77
Upside: +175.99%